Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Pasithea, Evotec Ink Drug Development Pact

Author: Vandana Singh | October 11, 2021 08:34am

Pasithea Therapeutics Corp (NASDAQ:KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner.
No deal terms were disclosed.
Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia," stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
Price Action: KTTA shares closed 1.50% lower at $2.62 on Friday.

Posted In: EVOTF EVTCY KTTA